研究者詳細 - 田中　章仁

論文 - 田中　章仁

分割表示 77 件中 21 - 40 件目／全件表示 >>

Proliferative glomerulonephritis with monoclonal immunoglobulin deposits and atypical pathological findings treated with corticosteroid and rituximab 査読有り

Machi Mori, Akihito Tanaka, Kayaho Maeda, Shoji Saito, Kazuhiro Furuhashi, Shoichi Maruyama

CEN Case Rep 2023年8月

Prognosis and incidence of infections in chronic kidney disease patients with membranous nephropathy enrolled in a large Japanese clinical claims database 査読有り

Takuro Matsuzaki, Yu Watanabe, Akihito Tanaka, Kazuhiro Furuhashi, Shoji Saito, Shoichi Maruyama

BMC Nephrology 24 巻 ( 1 ) 頁： 126 2023年5月

Assessment of Antibody-Titer Changes after Second and Third Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccination in Japanese Post-Kidney-Transplant Patients 査読有り

Kumiko Fujieda, Akihito Tanaka , et al.

Vaccines (Basel) 11 巻 ( 1 ) 頁： 134 2023年1月

Influence of COVID-19 on the 10-year carbon footprint of the Nagoya University Hospital and medical research centre 査読有り

Hikaru Morooka, Takanori Yamamoto, Akihito Tanaka, Kazuhiro Furuhashi, Yasuhiro Miyagawa and Shoichi Maruyama

Globalization and Health 18 巻頁： 92 2022年11月

Mesenchymal stem cells exert renoprotection via extracellular vesicle-mediated modulation of M2 macrophages and spleen-kidney network 査読有り

Yuko Shimamura, Kazuhiro Furuhashi, Akihito Tanaka, et al.

Communication Biology 5 巻 ( 1 ) 頁： 753 2022年7月

Protocol for a Phase 1, Open-Label, Multiple-Center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 in the Treatment of Immunoglobulin A Nephropathy 査読有り

Tanaka Akihito, et al.

Frontiers in Medicine 9 巻頁： 883168 2022年5月

Antibody response to double SARS-CoV-2 mRNA vaccination in Japanese kidney transplant recipients 査読有り

Kumiko Fujieda, Akihito Tanaka, et al.

Scientific Reports 12 巻頁： 6850 2022年4月

Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease and Sleep Apnea Syndrome 査読有り

Yu Watanabe, Akihito Tanaka, et al.

Frontiers in Medicine 9 巻頁： 899359 2022年3月

Abnormal magnesium levels and their impact on death and acute kidney injury in critically ill children 査読有り

Morooka Hikaru, Tanaka Akihito, Kasugai Daisuke, Ozaki Masayuki, Numaguchi Atsushi, Maruyama Shoichi

PEDIATRIC NEPHROLOGY 2021年10月

記述言語：日本語出版者・発行元：Pediatric Nephrology

Background: The prevalence of magnesium imbalance in critically ill children is very high. However, its significance in the development of acute kidney injury (AKI) and mortality remains unknown. Methods: In this retrospective observational study from 2010 to 2018, the pediatric-specific intensive care database was analyzed. We included critically ill children aged > 3 months and those without chronic kidney disease. Patients were diagnosed with AKI, according to the Kidney Disease Improving Global Outcomes (KDIGO) study. We calculated the initial corrected magnesium levels (cMg) within 24 h and used a spline regression model to evaluate the cut-off values for cMg. We analyzed 28-day mortality and its association with AKI. The interaction between AKI and magnesium imbalance was evaluated. Results: The study included 3,669 children, of whom 105 died within 28 days, while 1,823 were diagnosed with AKI. The cut-off values for cMg were 0.72 and 0.94 mmol/L. Both hypermagnesemia and hypomagnesemia were associated with 28-day mortality (odds ratio [OR] = 2.99, 95% confidence interval [CI] = 1.89–4.71, p < 0.001; OR = 2.80, 95% CI = 1.60–4.89, p < 0.001). Hypermagnesemia was associated with AKI (OR = 1.52, 95% CI = 1.27–1.82, p < 0.001), while neither hypermagnesemia nor hypomagnesemia interacted with the AKI stage on the 28-day mortality. Conclusions: Abnormal magnesium levels were associated with 28-day mortality in critically ill children. AKI and hypermagnesemia had a strong association. Graphical abstract: “A higher resolution version of the Graphical abstract is available as Supplementary information”. [Figure not available: see fulltext.]

DOI： 10.1007/s00467-021-05331-1

Web of Science

Scopus

PubMed

Clustering phosphate and iron-related markers and prognosis in dialysis patients 査読有り

Hikaru Morooka, Akihito Tanaka, Daijo Inaguma, Shoichi Maruyama

Clin Kidney J 15 巻 ( 2 ) 頁： 328 - 337 2021年10月

A Case of TAFRO Syndrome with Two Consecutive Renal Biopsies Following the Pathological Course of the Kidney 査読有り

Kato, N; Hasegawa, T; Muto, R; Tanaka, A; Sato, Y; Maeda, K; Furuhashi, K; Saito, S; Kosugi, T; Maruyama, S

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 32 巻 ( 10 ) 頁： 823 - 824 2021年10月

Development of entrustable professional activities for residents rotating nephrology department in a Japanese university hospital: a Delphi study 査読有り

Tanaka A, et al.

BMJ Open 11 巻 ( 8 ) 頁： e047923 2021年8月

Utility of glomerular Gd-IgA1 staining for indistinguishable cases of IgA nephropathy or Alport syndrome. 査読有り

Ishiko S, Tanaka A, Takeda A, Hara M, Hamano N, Koizumi M, Ueno T, Hayashi H, Kondo A, Nagai S, Aoto Y, Sakakibara N, Nagano C, Horinouchi T, Yamamura T, Ninchoji T, Shima Y, Nakanishi K, Yoshikawa N, Iijima K, Nozu K

Clinical and experimental nephrology 25 巻 ( 7 ) 頁： 779 - 787 2021年7月

記述言語：英語出版者・発行元：Clinical and Experimental Nephrology

Background: Pathological findings in Alport syndrome frequently show mesangial proliferation and sometimes incidental IgA deposition, in addition to unique glomerular basement membrane (GBM) changes including thin basement membrane and/or lamellation. However, similar GBM abnormalities are also often observed in IgA nephropathy. Both diseases are also known to show hematuria, proteinuria, and sometimes macrohematuria when associated with viral infection. Therefore, it can be difficult to make a differential diagnosis, even based on clinical and pathological findings. Some recent articles demonstrated that galactose-deficient IgA1 (Gd-IgA1)-specific monoclonal antibody (KM55) could potentially enable incidental IgA deposition to be distinguished from IgA nephropathy. Methods: We performed comprehensive gene screening and glomerular Gd-IgA1 and type IV collagen α5 chain immunostaining for five cases with both IgA deposition and GBM changes to confirm that Gd-IgA1 can help to distinguish these two diseases. Results: Four of the cases were genetically diagnosed with Alport syndrome (Cases 1–4) and one was IgA nephropathy with massive GBM changes, which had a negative gene test result (Case 5). In Cases 1–4, glomerular Gd-IgA1 deposition was not detected, although there was positivity for IgA in the mesangial area. In Case 5, glomerular Gd-IgA1 deposition was observed. Conclusion: Gd-IgA1 expression analysis could clearly differentiate these two disorders. This approach can be applied to identify these two diseases showing identical clinical and pathological findings.

DOI： 10.1007/s10157-021-02054-3

Scopus

PubMed

Relationship between mortality and use of sodium bicarbonate at the time of dialysis initiation: a prospective observational study 査読有り

Morooka Hikaru, Yamamoto Junichiro, Tanaka Akihito, Inaguma Daijo, Maruyama Shoichi

BMC NEPHROLOGY 22 巻 ( 1 ) 頁： 118 2021年4月

記述言語：日本語出版者・発行元：BMC Nephrology

Background: Patients with chronic kidney disease often experience metabolic acidosis. Whether oral sodium bicarbonate can reduce mortality in patients with metabolic acidosis has been debated for years. Hence, this study was conducted to evaluate the utility of sodium bicarbonate in patients who will undergo dialysis therapy. In this study, we investigated the effect of oral sodium bicarbonate therapy on mortality in patients with end-stage kidney disease (ESKD) initiated on dialysis therapy. Methods: We conducted an observational study of patients when they started dialysis therapy. There were 17 centres participating in the Aichi Cohort Study of Prognosis in Patients Newly Initiated into Dialysis. Data were available on patients’ sex, age, use of sodium bicarbonate, drug history, medical history, vital data, and laboratory data. We investigated whether patients on oral sodium bicarbonate for more than three months before dialysis initiation had a better prognosis than those without sodium bicarbonate therapy. The primary outcome was defined as all-cause mortality. Results: The study included 1524 patients with chronic kidney disease who initiated dialysis between October 2011 and September 2013. Among them, 1030 were men and 492 women, with a mean age of 67.5 ± 13.1 years. Of these, 677 used sodium bicarbonate and 845 did not; 13.6% of the patients in the former group and 21.2% of those in the latter group died by March 2015 (p < 0.001). Even after adjusting for various factors, the use of sodium bicarbonate independently reduced mortality (p < 0.001). Conclusions: The use of oral sodium bicarbonate at the time of dialysis initiation significantly reduced all-cause mortality in patients undergoing dialysis therapy.

DOI： 10.1186/s12882-021-02330-0

Web of Science

Scopus

PubMed

MAGNESIUM IMBALANCE IS ASSOCIATED WITH 28-DAY MORTALITY IN CRITICALLY ILL CHILDREN: A RETROSPECTIVE OBSERVATIONAL ANALYSIS 査読有り

Hikaru Mrooka, Akihito Tanaka, et al.

Kidney international reports 6 巻 ( 4 ) 頁： S44 - S45 2021年4月

Peripheral artery disease at the time of dialysis initiation and mortality: a prospective observational multicenter study 査読有り

Morooka Hikaru, Tanaka Akihito, Inaguma Daijo, Maruyama Shoichi

BMJ OPEN 10 巻 ( 12 ) 2020年12月

Prognostic Impact of Parameters of Metabolic Acidosis in Critically Ill Children with Acute Kidney Injury: A Retrospective Observational Analysis Using the PIC Database 査読有り

Morooka Hikaru, Kasugai Daisuke, Tanaka Akihito, Ozaki Masayuki, Numaguchi Atsushi, Maruyama Shoichi

DIAGNOSTICS 10 巻 ( 11 ) 2020年11月

記述言語：日本語出版者・発行元：Diagnostics

Acute kidney injury (AKI) is a major complication of sepsis that induces acid-base imbalances. While creatinine levels are the only indicator for assessing the prognosis of AKI, prognostic importance of metabolic acidosis is unknown. We conducted a retrospective observational study by analyzing a large China-based pediatric critical care database from 2010 to 2018. Participants were critically ill children with AKI admitted to intensive care units (ICUs). The study included 1505 children admitted to ICUs with AKI, including 827 males and 678 females. The median age at ICU admission was 22 months (interquartile range 7–65). After a median follow-up of 10.87 days, 4.3% (65 patients) died. After adjusting for confounding factors, hyperlactatemia, low pH, and low bicarbonate levels were independently associated with 28-day mortality (respective odds ratio: 3.06, 2.77, 2.09; p values: <0.01, <0.01, <0.01). The infection had no interaction with the three parameters. The AKI stage negatively interacted with bicarbonate and pH but not lactate. The current study shows that among children with AKI, hyperlactatemia, low pH, and hypobicarbonatemia are associated with 28-day mortality.

DOI： 10.3390/diagnostics10110937

Web of Science

Scopus

PubMed

クロスマッチ陽性生体腎移植の臨床的検討査読有り

藤田高史, 加藤真史, 栃木宏介, 石田昇平, 舟橋康人, 松川宜久, 田中章仁, 齋藤尚二, 安田宣成, 丸山彰一

移植 55 巻 ( 0 ) 頁： 397_1 - 397_1 2020年

記述言語：日本語出版者・発行元：一般社団法人日本移植学会

<p>DSAは抗体関連型拒絶反応のリスク因子であり、①CDC陽性②FCXM陽性③FCXM陰性でDSA陽性の順にDSAの力価が高いと考えられている。クロスマッチ陽性腎移植における脱感作療法後のAMR発生率は12-60％と報告されているが、DSAの力価によりAMRの発生率は異なる。今回われわれは2011年から2019年までに当院で施行された生体腎移植の77例を対象として、FCXM陽性（グループ①、26例）、FCXM陰性でDSA陽性（グループ②、3例）、FCXM陰性（グループ③、48例）に分けて拒絶反応の発生率、CMV抗原血症、生着率について検討した。輸血、妊娠、移植の感作歴はグループ①、②、③でそれぞれ53.8%、33.3%、20.8%、DSAはグループ①に3例、グループ②に3例確認された。脱感作療法としてリツキシマブはグループ①、②、③でそれぞれ65.4%、100%、35.4%に投与されていた。AMRの発生率はグループ①、②、③でそれぞれ15.4%、33.3%、2.1%であった。CMV抗原血症に対してVGCの投与を要した症例はグループ①、②、③でそれぞれ15.3%、33.3%、29.2%であった。3年生着率はグループ①、②、③でそれぞれ100%、100%、92.4%であった。FCXM陽性例およびDSA陽性例はFCXM陰性例に比較するとAMRの発生率は高いが、短期生着率に差は認めなかった。</p>

DOI： 10.11386/jst.55.Supplement_397_1

Effect of Low-Density Lipoprotein Apheresis for Nephrotic Idiopathic Membranous Nephropathy as Initial Induction Therapy 査読有り

Therapeutic Apheresis and Dialysis 23 巻 ( 6 ) 頁： 575 - 583 2019年12月

Incidence rate of atrial fibrillation after dialysis initiation and its relationship with cardiovascular events 査読有り

Tanaka A, et al.

Acta Cardiologica 74 巻 ( 6 ) 頁： 527 - 535 2019年11月

　前のページ - 次のページ　

<田中 章仁>

論文 - 田中 章仁

<田中　章仁>

論文 - 田中　章仁